Unlabelled: Intravenous immunoglobulin (IVIG) use in non-approved indications, the increase in consumption and its high cost recommend rationalisation in its utilisation.
Aims: To assess the use of IVIG in Spanish hospitals.
Methods: An observational, prospective and multicentre drug utilisation study was conducted in 13 tertiary Spanish hospitals. Data were collected for 3 months in patients receiving any IVIG. Patient demographics, indication for IVIG use, dosage regimen and cost of treatment were collected.
Results: Five hundred and fifty-four patients (mean age of 52 years) were included in the study. A total of 1,287 prescriptions were administered, and the average number of prescriptions per patient was 2.3. The mean daily dose was 24 g (range 0.6-90 g). Overall, IVIG was prescribed for authorised indications in 335 patients (60%) with 953 prescriptions (74%), for non-authorised indications with scientific evidentiary support in 86 patients (16%) with 137 prescriptions (11%), and non-authorised and non-accepted indications in 133 patients (24%) with 197 prescriptions (15%). The most frequent authorised indications were primary and secondary immunodeficiencies, and the most frequent non-authorised and non-accepted indications were multiple sclerosis and bullous dermatosis. The mean cost of IVIG per patient for authorised indications was 2,636.2
Conclusions: IVIG is prescribed for a significant number of non-authorised and non-accepted indications with a notable cost. There is an important variability in IVIG prescriptions between hospitals, indicating room for improvement in IVIG use and the need for a consensus of protocol use.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00228-010-0800-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Correction to Mathieu D, Marroni A, Kot J: Tenth European Consensus Conference on Hyperbaric Medicine: recommendations for accepted and non-accepted clinical indications and practice of hyperbaric oxygen treatment. Diving Hyperb Med. 2017 Mar;47(1):24-32.
Diving Hyperb Med
June 2017
European Committee for Hyperbaric Medicine: Secretary General, Head of the National Center for Hyperbaric Medicine, Institute of Maritime and Tropical Medicine, Medical University of Gdansk, Poland,
Consistent with the Committee on Publication Ethics guidelines, we the above authors are initiating a partial retraction and correction of our paper: Mathieu D, Marroni A, Kot J: Tenth European Consensus Conference on Hyperbaric Medicine: recommendations for accepted and non-accepted clinical indications and practice of hyperbaric oxygen treatment. Diving Hyperb Med. 2017 Mar;47(1):24-32.
View Article and Find Full Text PDFTenth European Consensus Conference on Hyperbaric Medicine: recommendations for accepted and non-accepted clinical indications and practice of hyperbaric oxygen treatment.
Diving Hyperb Med
March 2017
European Committee for Hyperbaric Medicine.
The tenth European Consensus Conference on Hyperbaric Medicine took place in April 2016, attended by a large delegation of experts from Europe and elsewhere. The focus of the meeting was the revision of the European Committee on Hyperbaric Medicine (ECHM) list of accepted indications for hyperbaric oxygen treatment (HBOT), based on a thorough review of the best available research and evidence-based medicine (EBM). For this scope, the modified GRADE system for evidence analysis, together with the DELPHI system for consensus evaluation, were adopted.
View Article and Find Full Text PDFCommentary on the abuse of metal chelation therapy in patients with autism spectrum disorders.
J Med Toxicol
December 2013
University of Colorado School of Medicine and, Colorado School of Public Health, Denver, CO, USA,
Approximately half a million patients with autism spectrum disorders are subjected to chelation therapy in the US annually. The overwhelming majority of such cases are chelated for non-accepted medical indications. These patients may seek evaluation when a urine sample is assayed after the administration of a chelating agent and the values obtained have been improperly compared to references ranges for non-chelated urines, causing falsely elevated results.
View Article and Find Full Text PDFControversial issues in hyperbaric oxygen therapy: a European Committee for Hyperbaric Medicine Workshop.
Diving Hyperb Med
June 2011
National Center for Hyperbaric Medicine, Institute of Maritime and Tropical Medicine, Medical University of Gdansk, Poland.
Every few years, the European Committee for Hyperbaric Medicine (ECHM) publishes its recommendations concerning the clinical indications for hyperbaric oxygen therapy (HBOT). The last recommendations were issued during the 7th European Consensus Conference on Hyperbaric Medicine in 2004. Since then, several publications have reported on the use of HBOT in some indications in which it has not yet been recommended routinely, namely aseptic bone necrosis, global brain ischaemia and autism.
View Article and Find Full Text PDFUse of non-specific intravenous human immunoglobulins in Spanish hospitals; need for a hospital protocol.
Eur J Clin Pharmacol
June 2010
Clinical Pharmacology Department, Puerta de Hierro Majadahonda University Hospital, C/ Manuel de Falla 1, 28222, Majadahonda, Madrid, Spain.
Unlabelled: Intravenous immunoglobulin (IVIG) use in non-approved indications, the increase in consumption and its high cost recommend rationalisation in its utilisation.
Aims: To assess the use of IVIG in Spanish hospitals.
Methods: An observational, prospective and multicentre drug utilisation study was conducted in 13 tertiary Spanish hospitals.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!